Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1996 Aug;20(4):353-9.
doi: 10.1007/BF01486738.

Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency

Affiliations
Clinical Trial

Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency

W Pruzanski et al. Inflammation. 1996 Aug.

Abstract

The objective was to assess clinical efficacy of 3 dosages of intravenous gammaglobulins to prevent infectious episodes in adult common variable immunodeficiency. We designed a randomized, double blind, dose-assessing study. The setting was at University Hospital, Out-patient Clinic. Our patients were twenty-one adult patients with common variable immunodeficiency. The measurements were comparative study of the number and severity of infections using 3 various dosages of intravenous gammaglobulins, each given monthly for M least 6 months. Results indicated four hundred and eighty-four infectious episodes occurred while giving 305 infusions of IVIG 200 mg/kg; 205 infectious episodes while giving 170 infusions of 400 mg/kg and 436 infectious episodes while giving 247 infusions of 600 mg/kg. The morbidity scores (infection/infusion) were 1.59, 1.21 and 1.77 respectively (p - N/S). There was no significant difference in the severity of infections on the above 3 dosages, and no difference in the duration of infection-free intervals. The conclusions resulted in no significant differences in morbidity in adult patients with common variable immunodeficiency treated in cross-over pattern with IVIG 200 mg/kg, 400 mg/kg and 600 mg/kg. Thus, high dosages of IVIG are not conferring better protection against infections in such patients.

PubMed Disclaimer

References

    1. Immunol Rev. 1994 Jun;139:5-19 - PubMed
    1. J Lab Clin Med. 1988 Nov;112(5):634-40 - PubMed
    1. Clin Immunol Immunopathol. 1984 Apr;31(1):151-60 - PubMed
    1. Semin Hematol. 1992 Jul;29(3 Suppl 2):64-71 - PubMed
    1. Ann Intern Med. 1990 Feb 15;112(4):278-92 - PubMed

Publication types

Substances

LinkOut - more resources